Back to Search Start Over

Rosuvastatin-induced rhabdomyolysis: case report and call for proactive multifactorial risk assessment and preventive management of statin therapy in high-risk patients.

Authors :
Niedrig DF
Pyra M
Lussmann R
Serra A
Russmann S
Source :
European journal of hospital pharmacy : science and practice [Eur J Hosp Pharm] 2024 Apr 23; Vol. 31 (3), pp. 281-284. Date of Electronic Publication: 2024 Apr 23.
Publication Year :
2024

Abstract

Cholesterol-lowering statins are frequently prescribed for primary and secondary prevention of ischaemic vascular events. Whereas most patients tolerate statins without problems, statin-associated myopathy is well documented, as are several risk factors. We present a case report of an 80-90-year-old man with coronary artery disease who rapidly developed severe rhabdomyolysis during treatment with rosuvastatin while in intensive care. He had several concomitant risk factors for statin-induced myopathy including high dosage, old age, renal and hepatic impairment, and a pharmacogenetic SLCO1B1*1 a/*5 variant. Single known risk factors have a low predictive value for statin-induced myopathy and may therefore be underestimated in clinical practice. However, adverse drug reactions frequently involve the joint action of a multitude of environmental and genetic component causes, and statin-induced myopathy should be regarded as a multicausal event. We therefore advocate a proactive multifactorial risk assessment to guide and individualise statin therapy in high-risk patients.<br />Competing Interests: Competing interests: None declared.<br /> (© European Association of Hospital Pharmacists 2024. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ.)

Details

Language :
English
ISSN :
2047-9956
Volume :
31
Issue :
3
Database :
MEDLINE
Journal :
European journal of hospital pharmacy : science and practice
Publication Type :
Academic Journal
Accession number :
37451842
Full Text :
https://doi.org/10.1136/ejhpharm-2023-003765